Partial reprogramming of cells to restore youthful epigenetic patterns, and thus gene expression, is becoming quite the popular field of development. Based on results in mice, it is thought that the in vivo application of the Yamanaka factors could be made safe enough to be the basis for practical whole-body rejuvenation therapies. While epigenetic reprogramming can't do much for DNA damage and some of the persistent molecular waste found in old tissues, among other issues, it has been shown to restore lost mitochondrial function. It may ameliorate a range of other issues as well, and could prove to be beneficial enough to justify the present sizable investment into research and development, largely centered on Altos Labs. Funding attracts attention, and many others are joining in, with YouthBio Therapeutics being the latest new biotech company to throw its hat into the ring.
YouthBio Therapeutics, a longevity biotechnology company, has announced today its emergence out of stealth mode. YouthBio focuses on developing gene therapies aimed at epigenetic rejuvenation, particularly with the help of partial reprogramming by Yamanaka factors. The company was founded in early 2021 by Yuri Deigin and Viet Ly who will serve as its CEO and CFO, respectively. Dr. João Pedro de Magalhães will serve as the company's CSO and Dr. Alejandro Ocampo will serve as lead research collaborator.
"I am very optimistic that in the next 10 years science will provide humanity with major breakthroughs that will enable us to add decades of healthy life to people. Partial reprogramming is something I was always excited about as having the potential to be one such therapy. I am thrilled to take its research and development to the next level with the help of amazing colleagues."
"Cellular reprogramming allows us to rejuvenate cells and reset their biological clocks. It is the most important technology available today for developing rejuvenation therapies, although it still needs to be fine-tuned for effective and safe applications. Exploiting cellular reprogramming to develop therapies for age-related diseases is extremely exciting and, if successful, may result in a paradigm shift in medicine."